July 2024 Issue

Watch for Resmetirom to Treat NASH

Resmetirom (Rezdiffra) will be the first med approved for treatment of nonalcoholic steatohepatitis (NASH) with fibrosis in adults...


What is Prescriber's Letter?

Prescriber's Letter is the fastest, most trustworthy way to find out how drug therapy changes should fit into your practice, all while earning monthly CME credit. It's 100% free from financial support of the pharma industry. Learn more >

Unlock More

Prescriber's Letter is one of many medication advisory, CE, and training solutions from TRC Healthcare. We support prescribers of all kinds, at all stages of their career.

If you're a training decision-maker, learn more about our:

Group Purchases & Pricing

Prescriber's Letter is eligible for bulk discounts. Customize CE and compliance training assignments. Easily manage users and run reports. Bundle with other products for significant savings. Request information